Jump to content


New Tax Law Reduces Credit for Orphan Drugs in Half

  • Please log in to reply
No replies to this topic

#1 Jan0080


    Advanced Member

  • Members
  • PipPipPip
  • 51 posts
  • LocationLos Angeles

Posted 21 December 2017 - 06:13 PM

The new law reduces the credit for Orphan Drugs from 50% to 25%.

Currently, companies can claim a 50% tax credit for qualified clinical testing expenses incurred in testing certain drugs for rare diseases or conditions, generally referred to as "orphan drugs," affecting fewer than 200,000 persons in the US.

Starting in 2018, the credit will be 25%. This helps permit the manufacturers of our drugs to pay only 21% on their profits as opposed to 35%. Please don't expect any reduction in the cost of our medicine. This law has created a $1.5 Trillion dollar deficit. 

Real estate developers will have a top tax rate of 29.6% which is 20% lower than the 37% that our top earning Doctors will pay. Apparently, earning money from real estate is more important to society than physicians.

Diagnosed Dec 27, 2016 started Sprycel 100 mg Jan 7, 2017. Initial PCR 77.9 after 30 days 28.4, day 79 1.4 and day 115 0.1%. That is a 99.9% reduction! Sprycel 100 mg for 3 months, 80 mg for 1 month and now at 50 mg. Hooray for Sprycel!!! PCR June 5, 2017 0.04! Dose reduction to 40 mg 6/15/2017 due to shortness of breath. 20 mg as of June 29th. PCR .02 9/11/2017. PCR .015 IS as of 12/11/2017. Lungs substantially better. Low dose Sprycel works!

Adverse Effect - At about week 6 of Sprycel sharp muscle pain that would start at 2 AM and last for about 4 hours. This lasted about 4 weeks and went away, thank goodness.

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users